Preclinical and Toxicology Assessment of ALW-II-41-27, an Inhibitor of the Eph Receptor A2 (EphA2)

• Auteurs principaux: Theodore J. Kottom (Auteur), Kimberly E. Stelzig (Auteur), Madeline R. Pellegrino (Auteur), Marc Bindzus (Auteur), Eunhee S. Yi (Auteur), Andrew H. Limper (Auteur)
• Format: Livre
• Publié: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Background and Objective The EphA2 receptor inhibitor ALW-II-41-27 has proven to be an effective in vitro antagonist of Pneumocystis β-glucan-induced proinflammatory signaling. This suggests its potential as a candidate for initial anti-inflammatory drug testing in the rodent model of Pneum...